Abstract
The diagnostic criteria for slowly progressive type 1 diabetes (slowly progressive insulin-dependent diabetes mellitus; SPIDDM) have been revised by the Committee on Type 1 Diabetes of the Japan Diabetes Society. All of the following three criteria must be met for “a definitive diagnosis of SPIDDM”: (1) presence of anti-islet autoantibodies at some point in time during the disease course; (2) absence of ketosis or ketoacidosis at the diagnosis of diabetes with no requirement of insulin treatment to correct hyperglycemia immediately after diagnosis in principle; and (3) gradual decrease of insulin secretion over time, with insulin treatment required at more than 3 months after diagnosis, and presence of severe endogenous insulin deficiency (fasting serum C-peptide immunoreactivity < 0.6 ng/mL) at the last observed point in time. When a patient fulfills the only (1) and (2), but not (3), he/she is diagnosed with “SPIDDM (probable)” because the diabetes is non-insulin-dependent state.
This is a preview of subscription content, log in via an institution to check access.
Change history
07 March 2024
A Correction to this paper has been published: https://doi.org/10.1007/s13340-024-00702-z
References
Kobayashi T, Tamemoto K, Nakanishi K, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care. 1993;16:780–8.
Tanaka S, Ohmori M, Awata T, et al. Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the Committee on Slowly Progressive Insulin-Dependent (type 1) diabetes mellitus of the Japan Diabetes Society. Diabetol Int. 2015;6:1–7.
Urakami T, Suzuki J, Yoshida A, et al. Incidence of children with slowly progressive form of type 1 diabetes detected by the urine glucose screening at schools in the Tokyo Metropolitan Area. Diabetes Res Clin Pract. 2008;80:473–6.
Rajkumar V, Levine SN. Latent autoimmune diabetes. In: StatPearls. Treasure Island: StatPearls Publishing; 2022.
Zachariah S, Sharfi MO, Nussey SS, et al. Latent autoimmune diabetes in the young. Clin Med (Lond). 2008;8:552–3.
Kawasaki E, Maruyama T, Imagawa A, Diagnostic criteria for acute-onset type 1 diabetes mellitus, et al. Report of the Committee of Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus. Diabetol Int. 2012;2013(4):221–5.
Maruyama T, Tanaka S, Shimada A, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetesmellitus. J Clin Endocrinol Metab. 2008;93:2115–21.
Nishimura A, Matsumura K, Kikuno S, et al. Slowly progressive type 1 diabetes mellitus: current knowledge and future perspectives. Diabetes Metab Syndr Obes. 2019;12:2461–77.
Yasui J, Kawasaki E, Tanaka S, et al. Clinical and genetic characteristics of non-insulin-requiring glutamic acid decarboxylase (GAD) autoantibody-positive diabetes: a nationwide survey in Japan. PLoS ONE. 2016;11:e0155643.
Awata T, Shimada A, Maruyama T, et al. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther. 2017;8:1123–34.
Redondo MJ, Morgan NG. Heterogeneity and endotypes in type 1 diabetes mellitus. Nat Rev Endocrinol. 2023;19:542–54.
Buzzetti R, Tuomi T, Mauricio D, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes. 2020;69:2037–47.
Shimada A, Kawasaki E, Abiru N, et al. Diagnostic criteria of SPIDDM (2023). J Japan Diabetes Soc. 2023;66:587–91 (In Japanese).
Funding
This study is funded by Japan Diabetes Society.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Akira Shimada: lecture fee (Sanofi, Novo, Lilly, Terumo, Sumitomo, Abbott). Norio Abiru: lecture fee (Novo, Lilly). Haruhiko Osawa: research funding (Sysmex), scholarship donation (Daiichi-Sankyo, Novo). Tomoyasu Fukui: research funding (Cosmic). Junnosuke Miura: lecture fee (Terumo). Kazuki Yasuda: scholarship donation (Ono). Akihisa Imagawa: research funding (Parexel International, Taiho, MSD, Ono). Hiroshi Ikegami: lecture fee (Sanofi, Sumitomo, Terumo, Novo), scholarship donation (Sumitomo, Taisho, Life Scan, Novo). Other authors: nothing to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is the English version of “New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM)—Report from Committee on Type 1 Diabetes in Japan Diabetes Society”(https://doi.org/10.11213/tonyobyo.66.587) released in Japanese on Volume 66 Issue 7, 2023 on the official website of the Japan Diabetes Society, and has been jointly published in Journal of Diabetes Investigation(the official journal of AASD: https://doi.org/10.1111/jdi.14121) and Diabetology International (the official English journal of the Japan Diabetes Society).
Chairman: Prof. Hiroshi Ikegami. Reference items described in the Table of Japanese version is omitted in this English version because it is explained for the Japanese readers.
The authors have received approval from the editors of the Journal of the Japan Diabetes Society, Journal of Diabetes Investigation, and Diabetology International.
About this article
Cite this article
Shimada, A., Kawasaki, E., Abiru, N. et al. New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes in Japan Diabetes Society (English version). Diabetol Int 15, 1–4 (2024). https://doi.org/10.1007/s13340-023-00679-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13340-023-00679-1